Zoledronate-pulsed dendritic cell-based anticancer vaccines

Oncoimmunology. 2013 Sep 1;2(9):e25636. doi: 10.4161/onci.25636. Epub 2013 Jul 9.


The addition of zoledronate to tumor-associated antigen (TAA)-loaded dendritic cells (DCs) promotes the activation of interferon γ-secreting Vγ9 γδ T cells, in turn eliciting TAA-specific CD8+ T-cell responses. Immunological responses induced by zoledronate-pulsed DC-based vaccines have been associated with therapeutic effects in clinical trials.

Keywords: Wilms’ tumor 1; dendritic cell; electroporation; intratumoral injection; tumor-associated antigen-derived peptide; zoledronate.